Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Pharma giant Novo Nordisk on Wednesday reported booming demand for its weight loss and diabetes drugs Ozempic and Wegovy , but shares sank after the Danish firm disappointed investors with less-than-expected profits for the second quarter and a slimmed-down profit outlook for the year as it faces Novo Nordisk reported net profit of 20.05 billion Danish kroner in the second quarter of 2024, below consensus analyst estimates but an increase of 3% from the same time last year.
The figure marks an increase of a quarter from the same time period last year, when Novo pulled in $7.9 billion in sales. Overall, Novo said the GLP-1 class made up nearly half of sales in the first quarter, around $5.4 billion, up 33% from the same time last year, and the company raised sales expectations for the full year from 19% to 27% at constant exchange rates to 22% to 28%.
Eli Lilly Weight Loss Obesity Glp-1 Ozempic Wegovy Sales Shortages
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk stock price falls after Eli Lilly weight loss drug outperforms OzempicPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
California Goes Off The Rails—AgainSteve Forbes is Chairman and Editor-in-Chief of Forbes Media.
Read more »
Novo Nordisk shares dip as Wegovy maker posts earnings miss, cuts operating profit outlookNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
Read more »
Shares of Wegovy maker Novo Nordisk slide 5% after earnings missNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
Read more »
Shares of Wegovy maker Novo Nordisk slide 7% after earnings missNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
Read more »
Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlookNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
Read more »